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Following the publication of our article “Effectiveness of
agalsidase alfa enzyme replacement in Fabry disease: car-
diac outcomes after 10 years’ treatment” by Kampmann
et al. [1] we have become aware that the dose of agalsi-
dase alfa was not reported.
Eligible patients had a Fabry disease diagnosis con-
firmed by enzyme assay (males) and/or DNA analysis
(males and females), were aged ≥14 years at treatment
start, and had received agalsidase alfa (Replagal®; Shire,
Lexington, Massachusetts, USA) ERT at a dose of
0.2 mg/kg body weight every other week for approxi-
mately 10 years.
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